PMV Pharmaceuticals, Inc. 8-K

What Happened PMV Pharmaceuticals, Inc. (PMVP) filed a Current Report on Form 8‑K on March 6, 2026 announcing its results of operations and financial condition for the year ended December 31, 2025. The company issued a press release on March 6, 2026 with those results; the full text of the press release is attached to the 8‑K as Exhibit 99.1 and is incorporated by reference.

Key Details

• The 8‑K was filed under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
• Press release date: March 6, 2026; reporting period: year ended December 31, 2025.
• Exhibit 99.1 = press release; Exhibit 104 = Cover Page Interactive Data File (Inline XBRL).
• The filing is signed by Michael Carulli, Chief Financial Officer, dated March 6, 2026.

Why It Matters This filing formally notifies investors that PMV has published its full‑year 2025 financial results and made those results publicly available in a press release. Investors should review the attached press release (Exhibit 99.1) and the company’s subsequent filings for detailed figures (revenue, expenses, cash position, guidance) to assess financial performance and implications for the stock.